Kedrion Biopharma
Alessandro Materazzi is a professional in the pharmaceutical industry with a focus on sterility assurance and quality management. Currently serving as a Sterility Assurance & Risk Management Associate at Kedrion Biopharma since March 2024, Alessandro has previously held roles at the European Research Biology Center as a Quality Assurance Auditor and at Catalent Pharma Solutions as a Sterility Assurance Analyst. Key responsibilities include protocol development, risk assessment, and managing deviations related to sterility assurance. Alessandro also has experience in quality assurance documentation at Recipharm and contributed to microbiology research during a scholarship at the Università di Pisa. Educational credentials include a Master's degree in Molecular and Cell Biology and advanced studies in cGMP compliance and validation systems.
This person is not in any teams
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.